N6514
Neuraminidase from Vibrio cholerae
Type II, buffered aqueous solution, 8-24 units/mg protein (Lowry, using NAN-lactose)
Synonyme(s) :
Acyl-neuraminyl Hydrolase, Receptor-destroying enzyme, Sialidase
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
Numéro CAS:
UNSPSC Code:
12352204
NACRES:
NA.54
EC Number:
232-624-6
MDL number:
Specific activity:
8-24 units/mg protein (Lowry, using NAN-lactose)
Biological source:
Vibrio cholerae
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderbiological source
Vibrio cholerae
type
Type II
form
buffered aqueous solution
specific activity
8-24 units/mg protein (Lowry, using NAN-lactose)
foreign activity
Protease and NAN-aldolase, present
storage temp.
2-8°C
Quality Level
Vous recherchez des produits similaires ? Visite Guide de comparaison des produits
Catégories apparentées
General description
Calorimetry studies show that the two lectin-like domains flanking the central catalytic domain of Neuraminidase serve as the recognition and binding sites for sialic acid-containing substrates.
Neuraminidase enzymes are hydrolase enzymes that promote influenza virus release from infected cells and facilitate virus spread.
Application
Neurminidase is used as a cell-surface probe for glycoconjugate distribution and in substrate specificity studies.
Neuraminidase from Vibrio cholera has been used in a study to describe a five-step purification method. It has also been used in a study to investigate modification of leukemia L1210 tumor cells.
Physical form
Solution in 50 mM sodium acetate, pH 5.5, containing 0.15 M sodium chloride and 4 mM calcium chloride, 0.2 μm filtered..
Preparation Note
A further purification by affinity chromatography of our Type III.
Analysis Note
Preservative free.
Other Notes
One unit will liberate 1.0 μmole of N-acetylneuraminic acid per min at pH 5.0 at 37 °C using NAN-lactose or bovine submaxillary mucin, unless otherwise specified. Prices based on units using NAN-lactose as substrate.
signalword
Danger
hcodes
pcodes
Hazard Classifications
Resp. Sens. 1
Classe de stockage
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.
J G Bekesi et al.
Cancer research, 31(12), 2130-2132 (1971-12-01)
Paul Clark et al.
Viruses, 12(10) (2020-10-24)
Polyomaviruses are small, non-enveloped DNA tumor viruses that cause serious disease in immunosuppressed people, including progressive multifocal leukoencephalopathy (PML) in patients infected with JC polyomavirus, but the molecular events mediating polyomavirus entry are poorly understood. Through genetic knockdown approaches, we
Hirokazu Kai et al.
Bioorganic & medicinal chemistry, 20(8), 2739-2746 (2012-03-14)
A selective and potent inhibitor of neuraminidases, a hydrolase that is responsible for processing sialylated glycoconjugates, is a promising drug candidate for various infective diseases. The current study demonstrates that the use of an aglycone-focused library of 2-difluoromethylphenyl α-sialosides is
Ibrahim Moustafa et al.
The Journal of biological chemistry, 279(39), 40819-40826 (2004-07-01)
Vibrio cholerae neuraminidase (VCNA) plays a significant role in the pathogenesis of cholera by removing sialic acid from higher order gangliosides to unmask GM1, the receptor for cholera toxin. We previously showed that the structure of VCNA is composed of
Matthew D Lauver et al.
eLife, 9 (2020-09-18)
JCPyV polyomavirus, a member of the human virome, causes progressive multifocal leukoencephalopathy (PML), an oft-fatal demyelinating brain disease in individuals receiving immunomodulatory therapies. Mutations in the major viral capsid protein, VP1, are common in JCPyV from PML patients (JCPyV-PML) but
Contenu apparenté
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique